Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

Abstract
Elderly and poor performance status advanced non-small-cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Gefitinib (Iressa) was used in 59 elderly and/or unfit NSCLC pretreated patients participating in a compassionate use programme showing some activity and good tolerability.

This publication has 10 references indexed in Scilit: